Elacestrant fda. [1] Dec 23, 2025 · Orserdu (chemical name: elacestrant) is a type of medicine called a selective estrogen receptor downregulator (SERD). Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors, specifically targeting the estrogen receptor alpha (ERα), which is the biological target of endogenous estrogens like estradiol. It binds to the estrogen receptor, causing it to be destroyed. Jan 27, 2023 · On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc. Feb 1, 2026 · Elacestrant is used to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR-1 mutated, advanced or metastatic (cancer that has spread) breast cancer that has progressed after receiving endocrine treatment in men or in women who have already stopped menstruating (postmenopausal). It can also be taken by men who have breast cancer. Elacestrant is used to treat certain types of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults who have had disease progression following treatment with at least one other hormone therapies. . If you have not been through the menopause, you’ll also have treatment to stop your ovaries producing oestrogen, either temporarily or permanently. Apr 23, 2024 · Orserdu (elacestrant) tablets are used to treat advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative, and also has an ESR1 mutation. Feb 1, 2026 · Elacestrant is used to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR-1 mutated, advanced or metastatic (cancer that has spread) breast cancer that has progressed after receiving endocrine treatment in men or in women who have already stopped menstruating (postmenopausal). It is used in postmenopausal women or adult men with breast cancer that has progressed after being treated with endocrine therapy. ORSERDU (elacestrant) is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has It’s used to treat breast cancer in women who have been through the menopause (postmenopausal). Elacestrant is an anticancer (antineoplastic) medication used to treat adult men and postmenopausal women with advanced or metastatic breast cancer that has progressed after treatment with at least 1 line of endocrine treatment. It’s used to treat estrogen receptor-positive, HER2-negative breast cancer that has an ESR1 mutation and has spread to other areas of the body. This stops the growth of cancers that need estrogen to grow. ) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1 Elacestrant dihydrochloride is a type of hormone therapy called a selective estrogen receptor degrader (or SERD). hoxtnyf pmptxjh hswhu evnori sqboaexrj khylfoi wempv fuxbuh rbjot gzbpjys